Blood Cancer Journal
@BloodCancerJnl
Impact Factor 12.9. BCJ is part of Nature Portfolio of Journals. We publish high impact content on hematologic cancers. Editors: @VincentRK & Ayalew Tefferi
Our Current Treatment Algorithms section provides an expert outline for treatment of hematologic malignancies. See Myeloma algorithm by @VincentRK @myelomaMD @MayoCancerCare @MayoClinic #BCJ Experts interested in being an author should contact editors. nature.com/articles/s4140…
Integrated genomics with refined cell-of-origin subtyping distinguishes subtype-specific mechanisms of treatment resistance and relapse in diffuse large B-cell lymphoma | Blood Cancer Journal nature.com/articles/s4140…
🎙️Empowering Oncologists: The 3Ms of @JasmineKambojMD's life - Madras, Minnesota, Myeloma! From his roots in India to becoming a global leader at @MayoClinic, Dr. @VincentRK shares his inspiring journey, game-changing work in multiple myeloma, and the power of mentorship,…
A historic day for myeloma!! After 5 decades of research. European Commission / EMA approves Daratumumab as the first ever approved treatment for high risk smoldering myeloma based on the results of the AQUILA trial. @thanosdimop @PlasmaCellPete globenewswire.com/news-release/2…
Outcomes of teclistamab in patients with relapsed/refractory multiple myeloma with prior exposure to BCMA-directed therapy: a multicenter study from the U.S. Multiple Myeloma Immunotherapy Consortium @BloodCancerJnl share.google/OQEyPMbIqXfFos…
Managing IEC-associated enterocolitis following CAR-T therapy in multiple myeloma @BloodCancerJnl share.google/jxFIXxTF9Adhba…
Excited to share our latest article published in Blood Cancer Journal @BloodCancerJnl from Hokkaido Leukemia Net regarding duration of Venetoclax in AZA-VEN for AML patient. nature.com/articles/s4140…
Is immune effector cell-associated enterocolitis a CAR T-cell lymphoproliferative disorder? @BloodCancerJnl share.google/6purejcEDfu48W…
And the great companion @BloodCancerJnl piece to ours is now out too - should all non-infectious diarrhea after CAR-T for myeloma be presumed to be enteric T-cell lymphoma? They suggest yes, we suggest no... either way, we need better diagnostic tools! nature.com/articles/s4140…
1/ Now in @BloodCancerJnl: Algorithm for IEC-associated enterocolitis following CAR-T in myeloma. Companion #MMsm piece soon: how are you sure these aren't enteric T-cell lymphomas? In short, hard to say: oligoclonal expansion occurs & biologics often resolve Sx on their own.
Comparable outcomes with 14-, 21-, or standard 28-day venetoclax in the first cycle of azacitidine–venetoclax in untreated acute myeloid leukemia: real-world experience from the Hokkaido Leukemia Net @BloodCancerJnl share.google/QLhkbWQY8aBLWx…
Efficacy and safety of immunosuppressive therapy versus cyclosporine combined with avatrombopag in older adults with severe aplastic anemia: a multicenter prospective study @BloodCancerJnl share.google/PbkFv9MF0OlNew…
A retrospective study led by Dr. Zainab Shahid (@ZainabShd) at @MSKCancerCenter has analyzed #vaccine responses in patients who received post-#CARTCell therapy vaccination between 2018 and 2024. 💉 Read the @BloodCancerJnl study: go.nature.com/44LBNFf
📝 Guidelines for reporting cytogenetic results for MM risk stratification published in @BloodCancerJnl recommend including critical results and use of plain and standardized language. More news: MultipleMyelomaHub.com #MultipleMyeloma #myeloma #MedNews #MedEd
Incidental vs. symptomatic diagnosis of follicular lymphoma: implications of earlier detection | Blood Cancer Journal @MayoCancerCare nature.com/articles/s4140…
Fine particulate matter exposure is linked to worse myeloma outcomes in a diverse urban cohort | Blood Cancer Journal @aditishasMD nature.com/articles/s4140…
The clinical journey of belantamab mafodotin in relapsed or refractory multiple myeloma: lessons in drug development | Blood Cancer Journal @SagarLonialMD nature.com/articles/s4140…
Dexamethasone for the management of CRS Related to teclistamab in patients with relapsed/refractory multiple myeloma | Blood Cancer Journal nature.com/articles/s4140…
Novel humanized CD19-CAR-T (Now talicabtagene autoleucel, Tali-cel™) cells in relapsed/ refractory pediatric B-acute lymphoblastic leukemia- an open-label single-arm phase-I/Ib study | Blood Cancer Journal nature.com/articles/s4140…
Reduced venetoclax exposure to 7 days vs standard exposure with hypomethylating agents in newly diagnosed AML patients | Blood Cancer Journal nature.com/articles/s4140…
Sex-associated differences in outcome of patients with acute myeloid leukemia undergoing allogeneic hematopoietic stem cell transplantation | Blood Cancer Journal nature.com/articles/s4140…
A phase 2 study of Daratumumab with Thalidomide and dexamethasone in relapsed and/or Refractory Myeloma (RRMM) | Blood Cancer Journal @IMFmyeloma nature.com/articles/s4140…
